Newly diagnosed adults patients with Acute Myeloid Leukemia will be assessed as traditionally by the treating institution using classic clinical, demographic and cytogenetic variables. Complementary molecular tests will be performed in the patients included in the study using PCR to detect classic CBF (Core Binding Factor) rearrangements: CBFB-MYH11 [inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22). NGS (Next Generation Sequencing) to detect mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT](streamdown:incomplete-link)

Inclusion Criteria:

• Newly diagnosed AML
• Over 15 years of age
• Flow cytometry confirmation
• Candidate for treatment (intensive or not intensive)

Exclusion Criteria:

• Acute Promyelocytic Leukemia
• Mixed phenotype leukemias
• Isolated myeloid sarcoma
• Blastic plasmacytoid dendritic cell neoplasm

Mexican adults with newly diagnosed AML who are candidates for treatment (intensive or not intensive)